Nifuroxazide
A07A - Intestinal antiinfectives
ATC A07AX03
Small molecule
Natural product
JFDA label: Diarox Susp
Indications
Off-label
- Brain Diseases
- Inflammatory Bowel Diseases
Pregnancy & Lactation
Chemistry & Properties
| Formula | C12H9N3O5 |
|---|
| Molecular weight | 275.22 g/mol |
|---|
| IUPAC name | 4-hydroxy-N-[(E)-(5-nitrofuran-2-yl)methylideneamino]benzamide |
|---|
| CAS | 965-52-6 |
|---|
| PubChem CID | 5337997 |
|---|
| InChIKey | YCWSUKQGVSGXJO-NTUHNPAUSA-N |
|---|
| logP | 1.66 (XLogP 2.1) |
|---|
| Polar surface area | 117.97 Ų |
|---|
| H-bond acceptors / donors | 6 / 2 |
|---|
| Drug-likeness (QED) | 0.50 |
|---|
| Lipinski violations | 0 |
|---|
SMILES
O=C(N/N=C/c1ccc([N+](=O)[O-])o1)c1ccc(O)cc1Biology & Pharmacokinetics
Pharmacokinetics predicted
| Bioavailability | 70.0% |
|---|
| Half-life | 0.931 h |
|---|
| Volume of distribution | 0.467 L/kg |
|---|
| Protein binding | 96.3% |
|---|
| BBB penetrant | No |
|---|
Enzyme interactions
| Enzyme | Role | Detail |
|---|
| CYP1A2 | Inhibitor |
— |
| CYP2B6 | Inhibitor |
— |
| CYP2C8 | Inhibitor |
— |
| CYP2D6 | Substrate |
— |
| CYP3A4 | Inhibitor |
— |
| CYP3A4 | Substrate |
— |
Transporters
BCRP (Inhibitor)BSEP (Inhibitor)MRP1 (Inhibitor)OATP1B1 (Inhibitor)OATP1B3 (Inhibitor)P-gp (Inhibitor)P-gp (Substrate)
Registered Products (1)
| Brand | Form / strength | Pack | Agent | Citizen (JOD) |
|---|
| Diarox Susp
|
Suspension 220 mg/5 ml |
100 ml |
PHILADELPHIA PHAEMACEUTICALS.COMP/JORDAN |
2.400 |